Navigating the regulatory terrain down under: trends in Australia for 2024


Australia is the most populous country in Oceania, and ranks 55th globally with its population around 26 million. It also ranks consistently high in other indicators that demonstrate the country’s above-average wealth. Factors such as a skilled workforce, high-quality research infrastructure, government incentives and well developed regulatory and health technology assessment (HTA) frameworks encourage research and development (R&D) activities and continue to make Australia an attractive destination for therapeutic goods sponsors and manufacturers. Australia’s Therapeutic Goods Administration (TGA) sits at the centre of it all.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member